Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Results from the 12-week double-blind study period were previously published in The ... Results of the phase 2 OLE at week 48 showed: 96% of patients who continued receiving high-dose frexalimab ... Read More

New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial

Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results ... non-small cell lung cancer in patients whose disease has not progressed after CRT based on the PACIFIC Phase 3 trial. Read More

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

"We are excited to announce our fourth infectious disease vaccine program ... into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will ... Read More

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

PHOENIX Study Results: The Phase 3 PHOENIX ... R). Overall, reported rates of adverse events and discontinuations were similar between AMX0035 and placebo groups during the 24-week randomized ... Read More

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week ... results demonstrate that LPCN 1148 treatment benefits patients ... Read More

Reach a targeted audience

Immediately visible once published. Listed in Healthcare Dive's Press Release Feed. Featured in the Healthcare Dive daily newsletter — read by 114,000 industry decision-makers. Placed alongside ... Read More

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

The results ... in the hope of changing the hypertension treatment paradigm for patients. We are taking that next step with our recently initiated third Phase 2 study, KARDIA-3, designed to ... Read More

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

In the Phase 1 dose-escalation portion of the study, ascending dose levels of FG-3246 were administered every 3 weeks. In the dose-expansion arm of the trial, patients were treated at the 2.7 mg ... Read More

Submit a Press Release

All submissions are considered for publication in print and online. The submissions may be edited. We do not guarantee that every submission will be published. Read More

Sanofi - Aventis Groupe: Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Results from the 12-week double-blind study period were previously published (https ... Results of the phase 2 OLE at week 48 showed: 96% of patients who continued receiving high-dose frexalimab ... Read More

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease ... US. Results from the 12-week double-blind study period were previously published in The New England Journal ... Read More